Inspire Medical Systems, which spun out from Medtronic (NYSE:MDT) in 2007 and creates devices for treating obstructive sleep apnea, said last Friday it is looking to launch an initial public offering that could bring in as much as $86.3 million for the company.
Inspire Medical developed and produces a sleep apnea implant, a pacemaker-like system designed to stimulate nerves to keep airways open during sleep.
The Minneapolis-based company said it plans to offer shares under the NYSE ticker symbol “INSP”.
Last year, the company reported sales of $28.6 million and approximately $22.6 in gross profit, with $17.5 million in net losses, down from a reported $18.5 million in net losses reported in 2016.
The company has not yet said how many shares it plans to float in the offering. BofA Merrill Lynch and Goldman Sachs & Co are acting as underwriters for the offering, according to an SEC filing.
In November 2016, Inspire Medical closed a $37.5 million Series F financing round, as well as announcing the appointment of Marilyn Nelson to the board of directors.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.